See the difference! Customize Seeking Alpha: Sign in or join Seeking Alpha
Home The Macro View Stocks & Sectors Global Markets ETFs Investing Ideas News, Data, Transcripts Sign in or Join now
Home » Biotech Stocks » Long Ideas, Small Cap
<script type="text/javascript">GA_googleFillSlot_sa("Search_195x45_Dropdown");</script>
Loading...
Symbols:
Authors:
Peregrine Pharmaceuticals: Good Long Term Potential
by: VFC's Stock House June 16, 2010 | about: PPHM Font Size: PrintEmail Recommend 0 Share this page
Share0 VFC's Stock House 1275
Followers 4
Following FollowYou are currently following VFC's Stock House
Stop FollowingYou are no longer following VFC's Stock House
Profile
Articles (206)
StockTalks (1)
Comments (76)
Send Message About this author:
Visit: VFC's Stock House
Submit
an article to It's been a while since I've mentioned Peregrine Pharmaceuticals (PPHM), but I thought that the highs of April and May were a better time to sell than accumulate, so I left it alone. The mini-run earlier this year was based on a flurry of Press Releases outlining encouraging results from the ongoing Phase II trials that were to be presented at ASCO.
Now that the hype has died down a bit and the stock is back to trading for around three dollars, Peregrine Pharmaceuticals may be worth a look as a "Phase II accumulation" pick, with eyes towards the conclusion of the ongoing trials and the future potential of both Bavituximab and Cotara.
Bavituximab is an anti-tumor antibody that alerts one's immune system to attack the cancerous cells and is being investigated for effectiveness in multiple Phase II trials, including advanced breast cancer and other solid tumor indications. Peregrine is also testing this product for use in fighting infectious diseases, and Phase I trials for Hepatitis C and HIV are ongoing.
Cotara is classed as Tumor Necrosis Therapy [TNT] and carries anti-cancer agents into the core of the tumor, attacking them from the inside out. A Phase II trial testing this product in brain cancer patients is ongoing.
There's a lot of potential with these products, although it's worth keeping in mind that Phase II is a long way from market ,so it's worth it to keep a handful of trading shares in store to take advantage of any sudden spikes, like the one we saw during the April / May time frame.
That said, if either or both of these products make it through Phase III trials, then the share price will most likely be trading for much higher prices, so this stock is worth a look as a good mid to long term cancer pick for the current prices, in my opinion.
There's likely to be some additional volatility associated with this one being that significant news could still be months away, but it's likely that the company could offer up trial results late this year.
I like the potential of PPHM.
Disclosure: Long PPHM.
About the author: VFC's Stock House I'm VFC. After years of blowing through spare money and then starting a family, I decided it was time to bear down with the finances and look towards the future; after all, it wasn't just me I had to support anymore. I never trusted the stock market, but I also never trusted handing my hard... More Company: VFC's Stock House Blog: VFC's Stock House1275
Followers4
FollowingFollowSend Message Share this page
0
Share 0 Related Articles
• Gaining Exposure to Gold Through ETFs • Does the Bounce in the Euro Signal All Is Well? • Biflation or Stagflation? It Could Be Both Related stocks: PPHM
Related themes: Long Ideas, Small Cap, Biotech Diagnosis, Biotech Equipment, Biotech Research
Add Your Comment
GuestComment: Publish Submitting comment, please wait ...
PPHM vs. ETF AlternativesSymbol Today 3 Mths 1 Yr YTD
PPHM 1.0% -6.6% -36.3% 4.4%
ETF Alternatives
sponsored by 490,801 people have joined Seeking Alpha to track analysis of stocks they follow & exchange investment ideas
Join now (it's free):Choose Username
you can use your real nameEmail Address:Create Password:I agree to Terms of Use & Privacy Policy
Already joined? Sign inMost PopularWall Street Breakfast: Must-Know News
When to Buy BP
Cramer's Stop Trading! 2 Neglected Plays on Apple (6/14/10)
5 Reliable Dividend Stocks in the News
AT&T Melts Down Again, Will Apple Ever Learn?
3 Reasons This Rally Is Toast
Where Is BP Headed: $70 or $0?
Cramer's Lightning Round - Corning's Disappointments Are Over (6/14/10)
Cramer's Mad Money - Going GaGa Over the Bad Romance With Tech (6/14/10)
Just One Stock: A Thrift Where Being Conservative Pays Dividends
More »Editors' PicksCBOE: A Blue Chip IPO Without a Doubt
Schwab’s Low Fees Are Not About ETFs
Tough Times for Video Game Industry
Nokia: Valuation Appears Tempting but Concerns Remain
Understanding Employment Statistics
More »
The Seeking Alpha 100
The top 100 stock
market authors
selected for publication in the last week1
The Pragmatic... 2
David White 3
Philip Davis 4
John Lounsbury 5
Edward Harrison See all
Seeking Alpha 100 »
Fastest Climbers
Those with the largest
increase in followers
in the last week1
Wall St. Chea... 2
Jim Van Meerten 3
Dr. Kris 4
Gary Tanashian 5
MagicDiligence See all
Fastest Climbers »
Top Commenters
Top commenters,
as ranked by their peers1 User 353732 2 Moon Kil Woong 3 optionsgirl 4 Mayascribe 5 tripleblack See all
Top Commenters »
Top Instabloggers
The 100 most active
Instabloggers.1
Philip Davis 2
John Lounsbury 3
Cliff Wachtel 4
David Fry 5
Dr. Kris See all
Top Instabloggers »
Top StockTalkers
Top
StockTalkers.1
David White 2
Philip Davis 3
Andrew Wilkinson 4
Alan Brochstein 5
Cliff Wachtel See all
Top StockTalkers »
Free E-Newsletters
Wall Street Breakfast - Sample
The Macro View - Sample
Investing Ideas - Sample
Jim Cramer's Picks - Sample
Stocks & Sectors - Sample
Global Markets - Sample
Alt. Energy Investing - Sample
ETF Daily - Sample
The Daily Dispatch - Sample
We don't spam
Tools
Feeds About Seeking Alpha
About Seeking Alpha
Editorial principles
SA transcripts
The SA management
What's New
Who reads SA
SA Team Instablogs
David (Founder)
Eli (Editor in Chief)
Boaz (Contributor Relations) Contact
Contact us
Dispute an article
Advertise
SA Stats
Article stats
Instablog stats
StockTalk stats
Comment stats
Contributor stats For Contributors
Become a contributor
Contributor benefits
Seeking Alpha Certified
Feature your business / blog / book
Policy on anonymous contributors
For Journalists
SA for journalists
Interview a contributor
History and founder quote data from Xignite| Terms of use| Privacy| Copyright
Spell Checker X
Not Found
Replace With
Suggestions
Options
Delete
Replace
Ignore
Learn
Replace All
Ignore All
Spell Check Canceled!
Undo Corrections?
Yes No
Ignore All
Delete RepeatedIgnore
AI
